By Fineline Cube 
German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to evaluate BI 1815368. The trial will assess the efficacy, safety, and tolerability of this investigational drug in improving visual acuity for patients with diabetic macular edema (DME).
DME and BI 1815368
DME is a leading cause of vision loss among diabetic patients. BI 1815368 is an oral drug under investigation. It aims to treat and prevent macular leakage by reducing vascular permeability in neovascularization.-Fineline Info & Tech